Finally, the intense-debate over the FDA's denial to approve acomplia to be sold in the United States so far, now come to an end with the agency's staff disclosure on June 11. According to the agency's claim, the enhanced rate of psychiatric adverse effects is the core factor behind acomplia's delay. And a strong authentification to long-debated FDA's apprehension over the drug's neuropsychiatric side-effects is provided by its advisory panel of outside experts. The panel prepared a brief report revolving around the issues pertaining to acomplia's safety and efficacy.

A novel drug acomplia acts by jamming up the CB1 receptors found in the brain. The agency's staff report opines that without a positive response from the advisory panel, the drug maker can not make its way to the FDA approval and thus will has to wait till July when the FDA may decide on to defer the acomplia's approval for sale in the United States or not.

"Psychiatric disorders, particularity anxiety, sleep disorders and psychomotor agitation, are among the most significant adverse affects occurred during the phase-3 clinical trials", articulated the FDA staff.

The staff further figured out that during the clinical trails, a large number of participants withdrew quite early because of depression, anxiety and the need for antidepressant drug.

"Having considered the lack of organized record of such clinical subjects, the results prepared on the basis of these analyses should not be considered precise and must be regarded as a direct indication of rimonabant's risk for suicidality," the staff added.